• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Elutia Inc.

    10/15/24 6:59:31 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELUT alert in real time by email
    SC 13G 1 tm2426101d3_sc13g.htm SC 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. __)*

     

    Elutia Inc.

    (Name of Issuer)

     

    Class A Common Stock

    (Title of Class of Securities)

     

    05479K106

    (CUSIP Number)

     

    October 11, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

      

    CUSIP No. 05479K106 13G Page 2 of 10

     

    1.

    NAMES OF REPORTING PERSONS

     

    SilverArc Capital Management, LLC

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   
    ¨
    (b)   ¨
    3.

    SEC USE ONLY

     

    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    1,645,808
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    1,645,808
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,645,808

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)   
    ¨

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.53%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA

           

     

     

      

    CUSIP No. 05479K106 13G Page 3 of 10

     

    1.

    NAMES OF REPORTING PERSONS

     

    Devesh Gandhi

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a)   
    ¨
    (b)   ¨
    3.

    SEC USE ONLY

     

    4. CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING
    PERSON WITH

    5. SOLE VOTING POWER
     
    0
    6. SHARED VOTING POWER
     
    1,645,808
    7. SOLE DISPOSITIVE POWER
     
    0
    8. SHARED DISPOSITIVE POWER
     
    1,645,808
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,645,808

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)   
    ¨

     

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.53%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN

           

     

     

     

    CUSIP No. 05479K106 13G Page 4 of 10

     

    Item 1.

     

    (a)Name of Issuer

     

    Elutia Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

     

    2510 Prosperity Drive, Suite 370, Silver Spring, MD 20904

     

    Item 2.

     

    (a)Name of Person Filing

     

    SilverArc Capital Management, LLC (“SilverArc”) and Devesh Gandhi (“Gandhi” and together with SilverArc, the “Reporting Persons”)

     

    (b)Address of the Principal Office or, if none, residence

     

    20 Park Plaza, 4th Floor

    Boston, MA 02116

     

    (c)Citizenship

     

    SilverArc is a Delaware limited liability company. Gandhi is a citizen of the United States.

     

    (d)Title of Class of Securities

     

    Class A Common Stock

     

    (e)CUSIP Number

     

    05479K106

     

     

     

    CUSIP No. 05479K106 13G Page 5 of 10

     

    Item 3. If this statement is filed pursuant to Sec. 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)¨ Broker or dealer registered under section 15 of the Act (15 U.S.D. 78o):

     

    (b)¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c)¨  Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d)¨  Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e)x  An investment adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E);

     

    (f)¨  An employee benefit plan or endowment fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F);

     

    (g)x  A parent holding company or control person in accordance with Sec. 240.13d-1(b)(1)(ii)(G);

     

    (h)¨  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i)¨  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j)¨  A non-U.S. institution in accordance with Sec. 240.13d-1(b)(1)(ii)(J);

     

    (k)¨  Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J).

       

    Item 4. Ownership

     

    This statement is being filed with respect to an aggregate of 1,645,808 shares of Common Stock, resulting in beneficial ownership of Common Stock as follows:

     

    1.SilverArc

     

    (a)Amount Beneficially owned: 1,645,808.

     

    (b)Percent of Class: 5.53%.

     

    (c)Number of shares to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 1,645,808.

     

    (iii)Sole power to dispose or to direct the disposition of: 0.

     

    (iv)Shared power to dispose or to direct the disposition of: 1,645,808.

     

    2.Gandhi

     

    (d)Amount Beneficially owned: 1,645,808.

     

    (e)Percent of Class: 5.53%.

     

    (f)Number of shares to which the person has:

     

    (v)Sole power to vote or to direct the vote: 0.

     

    (vi)Shared power to vote or to direct the vote: 1,645,808.

     

    (vii) Sole power to dispose or to direct the disposition of: 0.

      

    (viii) Shared power to dispose or to direct the disposition of: 1,645,808.

     

     

      

    CUSIP No. 05479K106 13G Page 6 of 10

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    Not Applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of another Person.

     

    As of the date of this Report, SilverArc, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940, is deemed to be the beneficial owner of 1,645,808 shares, or 5.53% of the Common Stock believed to be outstanding, as a result of acting as investment adviser to various clients. Gandhi is the Sole Member of SilverArc and as such is deemed to be the beneficial owner of 1,645,808 shares, or 5.53% of the Common Stock believed to be outstanding. Clients of SilverArc have the right to receive and the ultimate power to direct the receipt of dividends from, or the proceeds of the sale of, such securities. SilverArc Capital Alpha Fund I, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 47,391 of these 1,645,808 shares, which equates to 0.16% of the Common Stock believed to be outstanding. SilverArc Capital Alpha Fund II, L.P., a Delaware limited partnership for which SilverArc acts as an investment adviser, may be deemed to beneficially own 1,057,644 of these 1,645,808 shares, which equates to 3.56% of the Common Stock believed to be outstanding. Squarepoint Diversified Partners Fund Limited, a Cayman Island exempted company for which SilverArc acts as investment adviser, may be deemed to beneficially own 361,191 of these 1,645,808 shares, which equates to 1.21% of the Common Stock believed to be outstanding. Atom Master Fund L.P., a Cayman Islands exempted limited partnership for which SilverArc acts as investment adviser, may be deemed to beneficially own 179,582 of these 1,645,808 shares, which equates to 0.60% of the Common Stock believed to be outstanding.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group.

     

    Not Applicable

     

     

     

     

    CUSIP No. 05479K106 13G Page 7 of 10

     

    Item 10.Certification

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Exhibits.

     

    Exhibit A  Joint Filing Agreement by and between the Reporting Persons dated October 11, 2024.

     

     

     

      

    CUSIP No. 05479K106 13G Page 8 of 10

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      October 15, 2024
      Date
       
    /s/ Devesh S. Gandhi  
     Devesh S. Gandhi, as Sole Member of SilverArc  
    Capital Management, LLC  
       
    /s/ Devesh S. Gandhi  
    Devesh S. Gandhi  

     

     

     

     

    CUSIP No. 05479K106 13G Page 9 of 10

     

    EXHIBIT INDEX

     

    Ex. Page No.
       
    A Joint Filing Agreement 10

     

     

     

     

    CUSIP No. 05479K106 13G Page 10 of 10

     

    EXHIBIT A

     

    JOINT FILING AGREEMENT

     

    The undersigned hereby agree that the statement on Schedule 13G with respect to the common stock of Elutia Inc., dated as of October 11, 2024, is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     

      October 15, 2024
      Date
       
    /s/ Devesh S. Gandhi  
    Devesh S. Gandhi, as Sole Member of SilverArc  
    Capital Management, LLC    
       
    /s/ Devesh S. Gandhi  
    Devesh S. Gandhi  

     

     

     

     

    Get the next $ELUT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELUT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ELUT
    SEC Filings

    View All

    Elutia Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ELUTIA INC. (0001708527) (Filer)

    3/4/26 8:00:18 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

    SCHEDULE 13G/A - ELUTIA INC. (0001708527) (Subject)

    2/17/26 4:36:43 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Elutia Inc.

    SCHEDULE 13G/A - ELUTIA INC. (0001708527) (Subject)

    2/13/26 5:05:45 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rakin Kevin bought $74,200 worth of shares (70,000 units at $1.06), increasing direct ownership by 56% to 196,120 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 5:01:40 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $20,800 worth of shares (20,000 units at $1.04), increasing direct ownership by 20% to 118,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 8:43:47 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $31,800 worth of shares (30,000 units at $1.06), increasing direct ownership by 44% to 98,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    1/29/26 5:51:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rakin Kevin bought $74,200 worth of shares (70,000 units at $1.06), increasing direct ownership by 56% to 196,120 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 5:01:40 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $20,800 worth of shares (20,000 units at $1.04), increasing direct ownership by 20% to 118,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    2/2/26 8:43:47 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Neels Guido J bought $31,800 worth of shares (30,000 units at $1.06), increasing direct ownership by 44% to 98,750 units (SEC Form 4)

    4 - ELUTIA INC. (0001708527) (Issuer)

    1/29/26 5:51:15 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Elutia Inc.

    SC 13G - ELUTIA INC. (0001708527) (Subject)

    10/15/24 6:59:31 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Elutia Inc. (Amendment)

    SC 13G/A - ELUTIA INC. (0001708527) (Subject)

    2/20/24 12:03:03 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Leadership Updates

    Live Leadership Updates

    View All

    Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

    GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where breast reconstruction represents the largest and most underserved opportuni

    3/2/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Where Purpose Meets Performance: Elutia Earns 2026 Great Place to Work Certification™

    GAITHERSBURG, Md., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has been Certified™ by Great Place to Work®, the leading organization that evaluates workplace culture through a standardized, anonymous employee survey methodology developed over 30 years of research. The certification recognizes organizations with high-trust workplace cultures, where sustained engagement and retention support consistent execution in regulated, innovation-driven industries. "Elutia isn't for everyone," said Dana Yoo, PhD, VP of Product Development. "The bar is high, and the work is hard. But

    2/18/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia Appoints Accomplished MedTech Veteran Guido J. Neels to Board of Directors

    Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, announced the appointment of Guido J. Neels to the Company's Board of Directors. Mr. Neels will also serve as a member of the audit committee of the Board. In conjunction with Mr. Neels' appointment, W. Matthew Zuga and Maybelle Jordan have both stepped down as members of Elutia's Board. "Randy and I are excited to welcome Guido to our Board of Directors and the Elutia CRU," said Kevin Rakin, Executive Chairman of Elutia. "G

    10/10/25 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Financials

    Live finance-specific insights

    View All

    Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

    GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    2/25/26 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia Reports Third Quarter 2025 Financial Results; Closes $88 Million Sale of BioEnvelope Business to Boston Scientific Corporation; Funds NXT-41x Development

    - Rapidly advancing NXT-41x to address significant unmet medical need for plastic and reconstructive surgery, which represents an estimated $1.5 billion U.S. market opportunity Conference call today at 5:00 p.m. ET / 2:00 p.m. PT GAITHERSBURG, Md., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial results for the third quarter of 2025. Business Highlights: BioEnvelope Business Sold to Boston Scientific Corporation for $88 Million: Transaction closed October 1, 2025, with proceeds used to eliminate debt and fund NXT-41x development program.Advancing Nex

    11/6/25 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

    GAITHERSBURG, Md., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    10/23/25 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELUT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elutia Regains Compliance with Nasdaq Listing Requirements

    GAITHERSBURG, Md., March 04, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it has received notice from Nasdaq that Elutia has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) and the minimum market value of listed securities requirement set forth in Nasdaq Listing Rule 5550(b)(2). As a result, the Company is now in full compliance with all Nasdaq continued listing requirements, and Nasdaq has advised that these matters are now closed. The Company's Class A common stock will continue to be listed and traded on the Nasdaq Capital Marke

    3/4/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia Selects Pete Ligotti as CCO to Lead the Commercial Launch of NXT-41x and Transform Post-Mastectomy Care in the $1.5B U.S. Breast Surgery Market

    GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced the appointment of Pete Ligotti as Chief Commercial Officer. Mr. Ligotti will lead the commercialization for NXT-41x, Elutia's next-generation antibiotic-eluting biomatrix being developed to improve outcomes in plastic and reconstructive surgery. NXT-41x is Elutia's next-generation antibiotic-eluting biomatrix, built on the Company's validated drug-eluting platform. Elutia is applying that platform in plastic and reconstructive surgery, where breast reconstruction represents the largest and most underserved opportuni

    3/2/26 8:00:00 AM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elutia to Report Fourth Quarter 2025 Financial Results on Wednesday, March 11, 2026

    GAITHERSBURG, Md., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (NASDAQ:ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix technologies, today announced that it will release its fourth quarter 2025 financial results after market close on Wednesday, March 11, 2026. Members of the Company's management team will host a conference call and webcast starting at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time on the same day. The conference call can be accessed using the following information: Webcast: Click here Dial-In: Click here To receive the dial-in number, as well as your personalized PIN, you must register at the above link. Once registered, you will also have the

    2/25/26 4:05:00 PM ET
    $ELUT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care